2-({[4-(5-methyl-3-phenylisoxazol-4-yl)-phenyl]-sulfonyl}-amino)-2-oxoethyl nitrate | 685107-06-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-({[4-(5-methyl-3-phenylisoxazol-4-yl)-phenyl]-sulfonyl}-amino)-2-oxoethyl nitrate
• 英文别名: [2-[[4-(5-Methyl-3-phenyl-1,2-oxazol-4-yl)phenyl]sulfonylamino]-2-oxoethyl] nitrate
• CAS: 685107-06-6
• 化学式: C₁₈H₁₅N₃O₇S
• 分子量: 417.399
• InChiKey: XREZMUOPYQVIPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  153
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• [EN] NITRIC OXIDE RELEASING SELECTIVE CYCLOOXYGENASE-2 INHIBITORS<br/>[FR] INHIBITEURS SELECTIFS DE LA CYCLO-OXYGENASE-2 LIBERANT DE L'OXYDE NITRIQUE
  申请人：MERCK FROSST CANADA INC

  公开号：WO2004037798A1

  公开（公告）日：2004-05-06

  The invention encompasses novel compounds of Formula (I) and Formula (II), which are nitric oxide-releasing prodrugs useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I) or Formula (II). The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.

  该发明涵盖了式(I)和式(II)的新化合物，这些化合物是一氧化氮释放前药，在治疗环氧合酶-2介导的疾病方面非常有用。该发明还涵盖了某些药物组合以及治疗环氧合酶-2介导的疾病的方法，包括使用式(I)或式(II)的化合物。上述化合物可以与低剂量阿司匹林联合治疗慢性环氧合酶-2介导的疾病或症状，同时降低血栓性心血管事件的风险。
• Nitric oxide releasing selective cyclooxygenase-2 inhibitors
  申请人：Wang Zhaoyin

  公开号：US20060058363A1

  公开（公告）日：2006-03-16

  The invention encompasses novel compounds of Formula (I) and Formula (II), which are nitric oxide-releasing prodrugs useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions and methods for treatment of cyclooxygenase-2 mediated diseases comprising the use of compounds of Formula (I) or Formula (II). The above compounds may be used as a combination therapy with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions while simultaneously reducing the risk of thrombotic cardiovascular events.

  本发明涉及化合物公式（I）和公式（II）的新型化合物，它们是一种释放一氧化氮的前药，可用于治疗环氧合酶-2介导的疾病。本发明还涉及某些药物组合和治疗环氧合酶-2介导的疾病的方法，包括使用公式（I）或公式（II）的化合物。上述化合物可与低剂量阿司匹林一起用于治疗慢性环氧合酶-2介导的疾病或病况，同时降低血栓性心血管事件的风险。
• NITRIC OXIDE RELEASING SELECTIVE CYCLOOXYGENASE-2 INHIBITORS
  申请人：MERCK FROSST CANADA & CO.

  公开号：EP1562914A1

  公开（公告）日：2005-08-17